Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury

Am J Physiol Heart Circ Physiol. 2004 Jan;286(1):H276-82. doi: 10.1152/ajpheart.00129.2003. Epub 2003 Sep 11.

Abstract

Previous studies indicate that deficiency of endothelial nitric oxide (NO) synthase (eNOS)-derived NO exacerbates myocardial reperfusion injury. We hypothesized that overexpression of eNOS would reduce the extent of myocardial ischemia-reperfusion (MI/R) injury. We investigated two distinct strains of transgenic (TG) mice overexpressing the eNOS gene (eNOS TG). Bovine eNOS was overexpressed in one strain (eNOS TG-Kobe), whereas the human eNOS gene was overexpressed in the other strain (eNOS TG-RT). Non-TG (NTG) and eNOS TG mice were subjected to 30 min of coronary artery occlusion followed by 24 h of reperfusion, and the extent of myocardial infarction was determined. Myocardial infarct size was reduced by 33% in the eNOS TG-Kobe strain (P < 0.05 vs. NTG) and by 32% in the eNOS TG-RT strain (P < 0.05 vs. NTG). However, postischemic cardiac function (cardiac output, fractional shortening) was not improved in the eNOS TG-Kobe mouse at 24 h of reperfusion [P = not significant (NS) vs. NTG]. In additional studies, eNOS TG-Kobe mice were subjected to 30 min of myocardial infarction and 7 days of reperfusion. Fractional shortening and the first derivative of left ventricular pressure were measured in eNOS TG-Kobe and NTG mice, and no significant differences in contractility were observed (P = NS) between the eNOS TG mice and NTG controls. Left ventricular end-diastolic pressure was significantly (P < 0.05 vs. NTG) reduced in the eNOS TG-Kobe strain at 7 days of reperfusion. The cardioprotective effects of eNOS overexpression on myocardial infarct size were ablated by Nomega-nitro-l-arginine methyl ester (300 mg/kg) pretreatment. Thus genetic overexpression of eNOS in mice attenuates myocardial infarction after MI/R but fails to significantly protect against postischemic myocardial contractile dysfunction in mice.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alkenes / pharmacology
  • Animals
  • Cattle
  • Decanoic Acids / pharmacology
  • Echocardiography
  • Heart / physiopathology
  • Hemodynamics
  • Humans
  • Hydroxy Acids / pharmacology
  • Mice
  • Mice, Inbred Strains
  • Mice, Transgenic
  • Myocardial Infarction / pathology
  • Myocardial Ischemia / diagnostic imaging
  • Myocardial Ischemia / pathology*
  • Myocardial Ischemia / physiopathology*
  • Myocardial Reperfusion Injury / diagnostic imaging
  • Myocardial Reperfusion Injury / pathology*
  • Myocardial Reperfusion Injury / physiopathology*
  • Myocardium / enzymology*
  • Nitric Oxide Donors / pharmacology
  • Nitric Oxide Synthase / metabolism*
  • Nitric Oxide Synthase Type II
  • Nitric Oxide Synthase Type III
  • Time Factors

Substances

  • Alkenes
  • Decanoic Acids
  • Hydroxy Acids
  • Nitric Oxide Donors
  • dipropylenetriamine-NONOate
  • 5-hydroxydecanoic acid
  • NOS3 protein, human
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse